Skip to main content

Table 4 SVR12 valuesa for clinical-trial regimens with and without RBV in patients who were (i) cirrhotic or non-cirrhoticb, (ii) treatment-experienced or -naïve, or (iii) HIV-positive or -negative

From: Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review

Regimen SVR12% [95% CI]
Cirrhotic Non-cirrhotic Treatment-experienced Treatment-naïve HIV-positive HIV-negative
DCV + SOF containing regimens
 DCV + SOF +RBV 87.3
[74.1, 96.9]
n = 42
95.5
[76.0, 100.0]
n = 16
NR 100.0
[68.3, 100.0]
n = 5
NR 100.0
[68.3, 100.0]
n = 5
−RBV 62.5 [44.9, 78.6]
n = 32
97.4
[93.2, 99.8]
n = 136
90.8
[79.6, 98.4]
n = 55
91.7
[87.9, 94.9]
n = 328
92.3
[69.9, 100.0]
n = 13
89.6
[84.1, 94.2]
n = 165
GZR containing regimens
 GZR + EBR + MK-3682 +RBV NR NR NR NR NR NR
−RBV NR 88.4
[76.8, 96.5]
n = 43
NR 88.4
[76.8, 96.5]
n = 43
NR 88.4
[76.8, 96.5]
n = 43
 GZR + RZR + MK-3682 +RBV NR NR NR NR NR NR
−RBV NR 93.0
[83.1, 99.1]
n = 43
NR 93.0
[83.1, 99.1]
n = 43
NR 93.0
[83.1, 99.1]
n = 43
 GZR + EBR + SOF +RBV NR NR NR NR NR NR
−RBV 90.9
[65.0, 100.0]
n = 11
96.6
[85.8, 100.0]
n = 29
NR 95.0
[85.5, 99.9]
n = 40
NR 95.0
[85.5, 99.9]
n = 40
LDV containing regimens
 LDV + SOF +RBV 79.1
[68.3, 88.3]
n = 67
93.2
[87.0, 97.7]
n = 98
82.0
[70.0, 91.6]
n = 50
91.3
[87.3, 94.7]
n = 246
NR 88.2
[79.8, 94.6]
n = 76
−RBV NR NR NR 64.0
[44.0, 81.9]
n = 25
NR 64.0
[44.0, 81.9]
n = 25
OBV containing regimens
 OBV + PTV/r +RBV NR 50.0
[18.9, 81.1]
n = 10
NR 50.0
[18.9, 81.1]
n = 10
NR 50.0
[18.9, 81.1]
n = 10
−RBV NR 9.1
[0.0, 35.0]
n = 11
NR 9.1
[0.0, 35.0]
n = 11
NR 9.1
[0.0, 35.0]
n = 11
 OBV + PTV/r + SOF +RBV NR 90.9
[65.0, 100.0]
n = 11
NR NR NR NR
−RBV NR 100.0
[81.7, 100.0]
n = 9
NR NR NR NR
PIB containing regimens
 PIB + GLE +RBV 100.0
[93.0, 100.0]
n = 24
NR NR 100.0
[93.0, 100.0]
n = 24
NR 100.0
[93.0, 100.0]
n = 24
−RBV 100.0
[93.0, 100.0]
n = 24
94.6
[88.5, 98.7]
n = 89
66.7
[5.9, 100.0]
n = 3
98.0 [92.9, 100.0]
n = 80
NR 97.1 [91.7, 100.0]
n = 83
 PIB + PTV/r +RBV NR 90.0
[61.9, 100.0]
n = 10
NR 90.0
[61.9, 100.0]
n = 10
NR 90.0
[61.9, 100.0]
n = 10
−RBV NR NR NR NR NR NR
VEL containing regimens
 VEL100 + SOF +RBV 93.3
[82.2, 99.7]
n = 39
100.0
[93.5, 100.0]
n = 26
98.1
[91.9, 100.0]
n = 52
NR NR 98.1
[91.9, 100.0]
n = 52
−RBV 84.7
[77.8, 90.6]
n = 132
97.6
[95.1, 99.4]
n = 278
92.1
[86.4, 96.4]
n = 124
97.3
[94.6, 99.2]
n = 260
91.7
[67.6, 100.0]
n = 12
93.9
[87.2, 98.5]
n = 80
 VEL100 + SOF + VOX +RBV NR NR NR NR NR NR
−RBV 92.9
[83.9, 98.8]
n = 55
100.0
[92.0, 100.0]
n = 21
98.7
[92.7, 100.0]
n = 54
94.4
[86.1, 99.4]
n = 57
NR NR
SOF containing regimens
 SOF +RBV 70.1
[65.9, 74.0]
n = 540
82.8
[80.4, 85.18]
n = 1039
77.2
[73.0, 81.2]
n = 430
81.1
[79.0, 83.1]
n = 1453
80.4
[75.5, 84.8]
n = 283
58.5
[53.2, 63.6]
n = 344
−RBV NR NR NR NR NR NR
Peg-IFN containing regimens
 Peg-IFN +RBV 43.6
[35.1, 52.4]
n = 140
75.4
[69.3, 81.2]
n = 256
NR 69.1
[67.4, 70.9]
n = 2928
55.3
[43.0, 67.3]
n = 69
64.0
[61.6, 66.4]
n = 1752
−RBV NR NR NR NR NR NR
 Peg-IFN + SOF +RBV 94.3
[90.0, 97.7]
n = 201
94.0
[87.4, 98.7]
n = 119
70.9
[63.7, 77.7]
n = 170
99.1
[94.8, 100.0]
n = 133
100.0 [30.3, 100.0]
n = 2
83.3
[65.4, 96.0]
n = 24
−RBV NR NR NR NR NR NR
  1. CI confidence interval, DCV daclatasvir, EBR elbasvir, GLE glecaprevir, GZR grazoprevir, I-Sq I2, LDV, ledipasvir, NR not reported, OBV ombitasvir, Peg-IFN pegylated interferon, PIB pibrentasvir, PTV paritaprevir, RBV ribavirin, r ritonavir, SOF sofosbuvir, RZR ruzasvir, VEL100 velpatasvir 100 mg, VOX voxilaprevir
  2. aWhere SVR12 was not available, SVR24 was used
  3. bCohorts were considered non-cirrhotic if 0% of patients were cirrhotic. Where SVR12 values of 100% are presented, this may be due to clinical trials that were exclusively HIV-positive or -negative, exclusively treatment-experienced or -naïve, or exclusively cirrhotic or non-cirrhotic